Nov 2021

Possible Solution to Endometriosis? Oxidative Stress – Molecular hydrogen – Antioxidants – Endometriosis This article is not like my previous blogs. This one is more research orientated and somehow I believe in this one strongly. First, I am not a medical doctor and I am not providing any medical advice. This is simply my views as a sufferer of endometriosis and my quest to bring information to people.  This also is a request to the medical authorities and healthcare department to look into it more thoroughly and find a systematic, regular basis (monthly/ weekly) treatment for endometriosis patients – Antioxidants based or molecular hydrogen based therapy

Learn More
Oct 2021

Break-up with Caffeine!

  • By: Priyanka Shinde

When I was diagnosed with Endometriosis in early 2020, doctors asked me to experiment with my diet. One of the first steps were going dairy free and caffeine free. My instant reaction - "I can't stop drinking the coffee! I stop drinking coffee, I stop doing the standing, and the walking, and the words-putting-into-sentences doing." Literally my case 2 years back! Everything was about coffee. My morning – start of office – post lunch – evening break – after work; My friends argued about me having caffeine in my veins more than blood. The aroma of coffee itself was intoxicating for me. Being thrown into the uncharted territory of learning to live

Learn More

You could fly to the moon 456 times before getting an Endometriosis Diagnosis, study finds. - Alice Broster of Forbes recently published an article that gives a peek into the life of women suffering from Endometriosis. In the time it takes for women to obtain an accurate diagnosis, she could -  fly to the moon 456 times, run 14,231 marathons, climb mount Everest 45 times! - Ughhh. This one got me.  I have said this before - #1in10 women! Currently, 200 million+ women are affected by this disease around the world. For us, this journey to the right diagnosis averages between 7 to 12 years. In some cases, it takes more than 14 years to just diagnose.

Learn More
Jul 2021

I am no Blogger. I am just here to share and hope to help more girls like me. A 30-year-old middle class girl from India. An Architect by profession. A basic girl who just wants to live her dreams. I am no writer. But ever since Endometriosis entered my ordinary life and made it extra-ordinary, I have a lot say. If I choose to share, I know that my vulnerability may help others finally receive their own diagnosis by learning about familiar symptoms. For those who have already been diagnosed, seeing me open up about my journey may help them feel less alone. I was lost. I was clueless. And I thought I was alone. The disease that affects 1 in 10 women, had me on my knees, left to feel

Learn More
Oct 2020

Endometriosis: But your tests are all negative?


So often we get questions in our Facebook group about diagnostic studies for endometriosis. Patients are told repeatedly, your MRI/CT Scan/US/colonoscopy showed nothing, so you are disease free. Often they are told by family, friends, and doctors alike to stop obsessing about their symptoms, because they do not have endometriosis. This makes the path to diagnosis long and difficult for the patient. Since classic endometriosis symptoms are so pervasive and painful, these women persist in seeking answers. Still, on average, it takes 9 years to get a diagnosis. While scans can RULE IN endometriosis (particularly deep infiltrating endometriosis and endometriomas), they CANNOT

Learn More

TEMPLE THERAPEUTICS B.V. MOMENTUM BUILDS INTO $45M RAISE TO ADVANCE PIPELINE; WINS $3 MILLION FUNDING IN EUREKA EUROSTARS PROGRAMME TO DEVELOP NOVEL THERAPY FOR OVARIAN AND SOLID CANCERS (AUGUST 20th, 2019 – GELEEN, THE NETHERLANDS)-- Temple Therapeutics, B.V. (the “Company” or “Temple”), a clinical stage biotechnology company engaged in the development of first-in-class therapeutics for post-surgical adhesion prevention, endometriosis, and oncology, announced today that the Company and its consortium partners will be receiving non-dilutive funding of $3 million to develop a novel therapeutic based on the discovery of a novel target found in a

Learn More

Geleen, The Netherlands Temple Therapeutics BV (the “Company” or “Temple”)- September 10, 2018-Temple, a clinical stage biopharmaceutical company focused in developing therapeutics for fibrosis and oncology, announces the publication of groundbreaking mechanistic data for Evitar™ in Reproductive Sciences, a peer reviewed journal of the Society of Reproductive Investigations. Post-surgical adhesions are broadly recognized as the single greatest cause of surgical complications. Moreover, they have evaded effective intervention, until

Learn More

Temple Therapeutics B.V.'s vision is to “Challenge, Collaborate, Create” to bring innovative, impactful therapies which simplify and increase quality of life.  Achievement of which must be rooted in evidence, driven by science and the method of questioning. For 129 years, since Dembrowski’s first publication about post surgical adhesions, complete prevention is still elusive.  Advancement in science and those willing to challenge the paradigms led to the hypothesis that adhesion formation is the end result of an amplified fibrotic process.  Led by Temple's Chief Scientific Officer, Lynne Robertson, PhD.  and in collaboration with leading

Learn More

MeEt Us

View our upcoming events

View All Events